Corbus Pharmaceuticals Holdings (CRBP) Retained Earnings (2013 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) recorded quarterly Retained Earnings of -$555.4 million in Q4 2025, down 3.84% quarter-over-quarter from -$534.9 million in Q3 2025, and down 1587042.86% on a YoY basis from N/an in Q4 2024.
Corbus Pharmaceuticals Holdings (CRBP) Retained Earnings (2013 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' Retained Earnings history runs 13 years deep, the most recent figure standing at -$555.4 million for Q4 2025.
- In Q4 2025, Retained Earnings fell 1587042.86% year-over-year to -$555.4 million; the TTM figure through Dec 2025 stood at -$555.4 million (down 1587042.86% YoY), while the FY2025 annual figure was -$555.4 million, down 1587042.86% from the prior year.
- Retained Earnings was -$555.4 million for Q4 2025 at Corbus Pharmaceuticals Holdings, down from -$534.9 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $35000.0 in Q4 2024 to a low of -$555.4 million in Q4 2025.
- Historically, Retained Earnings has averaged -$282.0 million across 5 years, with a median of -$354.5 million in 2021.
- Biggest YoY gain for Retained Earnings was 100.01% in 2024; the steepest drop was 5816950.4% in 2024.
- A 5-year view of Retained Earnings shows it stood at -$349.7 million in 2021, then dropped by 12.11% to -$392.1 million in 2022, then slipped by 11.38% to -$436.7 million in 2023, then surged by 100.01% to $35000.0 in 2024, then sank by 1587042.86% to -$555.4 million in 2025.
- The last three Retained Earnings figures came in at -$555.4 million (Q4 2025), -$534.9 million (Q3 2025), and -$511.5 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -279.00 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | 130.89 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -838.07 Mn |
| 10 | Corbus Pharmaceuticals Holdings | 133.67 Mn | 105.86 Mn | - | -555.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -555.43 Mn |
| Sep 30, 2025 | -534.88 Mn |
| Jun 30, 2025 | -511.50 Mn |
| Mar 31, 2025 | -493.87 Mn |
| Dec 31, 2024 | 35,000.00 |
| Sep 30, 2024 | -467.40 Mn |
| Jun 30, 2024 | -388,000.00 |
| Mar 31, 2024 | -443.58 Mn |
| Dec 31, 2023 | -436.68 Mn |
| Sep 30, 2023 | -8,035.00 |
| Jun 30, 2023 | -418.61 Mn |
| Mar 31, 2023 | -68,469.00 |
| Dec 31, 2022 | -392.08 Mn |
| Sep 30, 2022 | -206,874.00 |
| Jun 30, 2022 | -119,320.00 |
| Mar 31, 2022 | -359.17 Mn |
| Dec 31, 2021 | -349.73 Mn |
| Sep 30, 2021 | -339.47 Mn |
| Jun 30, 2021 | -337.30 Mn |
| Mar 31, 2021 | -28,765.00 |